RxDoctor Payments Data

Lee Ciccarelli, MD

Geriatric Medicine · Williamsport, PANPI 1417909029

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by AstraZeneca at 53.6% of the total.

$456in general payments, 2019–2025

Across 13 payments — averaging $35.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$244
  • Pfizer$148
  • AbbVie$43
  • Astellas Pharma US Inc$21

What the payments were for

  • Food & beverage$456100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca2$244
Pfizer8$148
AbbVie2$43
Astellas Pharma US Inc1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$456 in reported general payments places this provider in the 70th percentile of 217 geriatric medicine providers in Pennsylvania.

See all geriatric medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$341,824
Medicare patients
223
Services billed
4,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban795$346,473
JardianceEmpagliflozin57$45,827
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$41,336
EntrestoSacubitril/Valsartan43$30,192
OzempicSemaglutide30$26,793
FarxigaDapagliflozin Propanediol51$24,914
Breo ElliptaFluticasone/Vilanterol61$21,407
JanuviaSitagliptin Phosphate16$15,554
Combivent RespimatIpratropium/Albuterol Sulfate24$12,332
ArexvyRsvpref3 Antigen/As01e/Pf31$10,054
Cinacalcet Hcl29$9,866
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$9,781
XareltoRivaroxaban13$6,923
Metoprolol Succinate336$6,189
Levothyroxine Sodium508$6,099

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$148$346,473795 claims
AstraZenecaFarxiga$244$24,91451 claims
AbbVieLumigan, Combigan$43$6,22424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 217 geriatric medicine providers in Pennsylvania.

Other geriatric medicine in Williamsport

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →